New octreotide pill faces off against current capsule in healthy volunteer study

NCT ID NCT07663318

Not yet recruiting Knowledge-focused Sponsor: Triastek (Shanghai) Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-stage trial in 18 healthy adults compares a new octreotide tablet (T25) with an existing capsule (MYCAPSSA) to see how much drug gets into the blood. It also checks whether a high-fat meal changes absorption of the tablet. Participants take single doses under fasting or fed conditions, and blood samples are collected over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

octreotide acetate

What this could lead to

If successful, this could help develop a more convenient oral form of octreotide for people with acromegaly.

What could go wrong

This is a very early Phase 1 study in only 18 healthy people, so results may not apply to patients or predict long-term effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY